FeesSafety
Pluang+

Neurosterix secures $105M Series B to advance schizophrenia drug NTX-253 to Phase 2 trials

Company Fundamentals
11 Nov 2026, 23:32 WIB
GlobeNewsWire
View Source
Bullish
Neurosterix secures $105M Series B to advance schizophrenia drug NTX-253 to Phase 2 trials

Neurosterix, a spin-out from Addex Therapeutics, has raised $105 million in a Series B funding round led by top life science investors. The funds will primarily support Phase 2 clinical trials of NTX-253, a selective muscarinic M4 positive allosteric modulator aimed at treating schizophrenia. This financing also backs Neurosterix's broader pipeline targeting neuropsychiatric disorders. Addex retains an 8.5% stake in Neurosterix, which is advancing innovative treatments with potential for safer, more effective neuropsychiatric care.

Neurosterix Series B financing is the subject, with $105 million raised for clinical trials. For readers following Health-sector stocks, here is Pluang's market snapshot as of Nov 12, 2026 04:11 WIB: out of 150 priced US stocks, 87 rose and 61 fell. Notable movers include NUWE at USD 5.58 (+6.49%), NVAX at USD 10.20 (-6.34%), and TNGX at USD 25.83 (+6.30%).

More News

AeroVironment wins $405M order for laser systems to boost Middle East counter-drone defense

AeroVironment wins $405M order for laser systems to boost Middle East counter-drone defense

AeroVironment secured a $405 million international order for its LOCUST X3 high-energy laser weapon systems, enhancing counter-drone defense capabilities in the Middle East amid rising regional security threats. Following the announcement, AeroVironm...

Market News
Bullish
49 minutes ago
Vestas Q3 2026 earnings and revenue miss estimates, shares fall and guidance is cut

Vestas Q3 2026 earnings and revenue miss estimates, shares fall and guidance is cut

Vestas Wind Systems reported Q3 2026 earnings per share of $0.13 and revenue of $6.34 billion, both below analyst expectations. The company's profit was impacted by weak sales volume and a broken turbine blade. Following the earnings miss, Vestas' sh...

Company Fundamentals
Bearish
53 minutes ago
Global beverage market to reach $2.78T by 2032, driven by nonalcoholic drinks and convenience trends.

Global beverage market to reach $2.78T by 2032, driven by nonalcoholic drinks and convenience trends.

The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...

Market News
Bullish
3 hours ago
Over 200 GLP-1 and incretin therapies in development are reshaping diabetes and obesity treatment landscapes.

Over 200 GLP-1 and incretin therapies in development are reshaping diabetes and obesity treatment landscapes.

DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...

Bullish
3 hours ago
Tennessee American Water issues over $84 in PFAS settlement credits per customer

Tennessee American Water issues over $84 in PFAS settlement credits per customer

Tennessee American Water has applied an additional $13.07 credit to customer accounts, bringing total PFAS settlement refunds to over $84 per customer. This credit follows approval from the Tennessee Public Utility Commission, allowing the company to...

Market News
Bullish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App